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ABSTRACT
  
Objective: Severe acute respiratory syndrome Coronavirus 2 causes both health and economic crises and up till now no drug or vaccine has yet 
been approved. There is an increased demand to explore other complementary methods to protect the world. Eucalyptus essential oil; a popular off-
label drug used to relieve nasal congestion via inhalation with promising effects on the upper respiratory diseases including viral infections. 
Methods: In order to provide review-based hypotheses demonstrating eucalyptus essential oil beneficial role; several published studies were 
retrieved from different databases and websites till June 2020. The retrieved data declared the antiviral potentials against viruses of same subgenus 
or with same pattern and the beneficial effects on respiratory system, immunity and overall health improvement, along with declaring the 
application methods and safety.  
Results: Off-label use of Eucalyptus essential oil by inhaling 12drops /150mL or 1.5% v/v solution boiling water may relief COVID-19 mild and 
moderate symptoms as pain, cough, respiratory inflammation, cytokine storm and dyspnea.  
Conclusions: Experimental and clinical data proved that inhalation of eucalyptus essential oil may provide the ability to reduce COVID-19 
patients symptoms and morbidity risk factors and may play a role as a preventative technique complementary to WHO guidance for beating 
COVID-19 virulence and transmission spread. 
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INTRODUCTION 
Corona virus disease 2019 (COVID-19) is a global 
pandemic of Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2). It first appeared in 
Wuhan, Hubei, China and then spreads all over the 
world through respiratory droplets, contact and the 
faecal-oral route1. World Health Organization (WHO) 
listed COVID-19 as a public health emergency of 
international concern due to its rapid and highly 
infectious pattern. The last WHO situation report-134 
up to date June 2, 2020 has confirmed a total number 
of infected peoples to be 6194533 from which 376320 
were died2. The nowadays pandemic is characterized 
by intensity variation between countries, misleading 
indication of case fatality rate and unclear data about 
the virus and its virulence. The absence of vaccines and 
treatments encouraged the control strategies role and 
non-pharmacological measurements for communities3. 
Several intervention therapeutic strategies were 
reported as an alternative approach to control the 
COVID-19 pandemic. From these strategies the 
inhalation of Eucalyptus essential oil (EEO) which 
reported in several publications in addition to folkloric 
traditional use in some countries during the few last 
days4-9. No clinical trial, in vivo or in vitro studies 
demonstrate the EEO activity against COVID-19; but 
several review-based expected potentials as antiviral, 
co-infection control, symptoms relief or just a safe 
hygienic lifestyle. Today many companies have 
advertised to EEO as a product for prevention or 
treatment of COVID-1910; but, US Food and Drug 
Administration (FDA) had sent a warning letters to 
such companies11. In this work I will declare both facts 
and problems of EEO use in controlling COVID-19 
pandemic. 
 
METHODS 
Literature search was performed using diffrent 
databases as; Science Direct, Google Scholar, Web of 
Science, PubMed, ClinicalTrials.gov and Scopus using 
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main key word “Eucalyptus” in addition to “COVID-
19, COPD, Antiviral, Anti-inflammatory, Immune 
modulation, Antimicrobial, clinical trials, FDA, 
Monograph, Inhalation and Potential”. 
  
DISCUSSION 
Off-label use of EEO:  EEO widely used as Over The 
Counter (OTC) drug in a single or combined form for 
relieving nasal congestion via inhaling a few drops 
either on a handkerchief or in a bowl of hot water12. 
Vapor inhalation of EEO relief symptoms of 
bronchitis, asthma, and chronic obstructive pulmonary 
disease (COPD) which are the risk factors in COVID-
19 patients13. Traditional use of EEO for relief of 
cough associated with cold are accepted without the 
supervision of a medical practitioner via inhalation and 
as a bath additive and had been described for a long 
time14. 1,8-Cineole the major constituent of EEO (80-
95%) is well tolerated in inhalation administrations and 
is registered as a licensed medicinal product which 
available for airways inflammation for many years15. 
As well Vicks VapoRub® vapors inhalation which 
containing eucalyptus, camphor and menthol acting on 
cold receptors in the nose are a common used off-label 
drug. The German Standard zulassung, the 
Pharmacopée Française and the WHO monograph 
2002 had reported the use of EEO for the treatment of 
respiratory tract disorders, bronchial catarrh and 
stomach pain14. The Martindale reported that EEO 
effective as an inhalant, often in combination with 
other volatile oils for catarrh and coughs in a lot of 
preparations16. EEO is approved by the FDA for food 
use (EAFUS -Everything Added to Food in the United 
States- list No 2081) [FDA 2013] and as OTC (Over 
the counter) drug in cough/cold monograph sub-
categories nasal decongestant (mouthwash or lozenge), 
antitussive and expectorant and in external analgesic 
monograph sub-categories counter irritant, fever 
blister/cold sore and poison ivy/oak/sumac and in skin 
protectant monograph sub-categories astringent and 
poison (ivy/oak/sumac)17. 
COPD control by EEO: COPD is associated with 
increased risk of morbidity in COVID-19 patients18. 
Pretreatment with EEO markedly reduced the 
production TNF-α and IL-β proinflammatory 
cytokines, superoxide dismutase (SOD) activity and 
malondialdehyde (MDA) level which indicates that 
EEO might have its potential in COPD treatment19. The 
anti-inflammatory effect EEO to reduce cytokine 
release was confirmed also in ex-vivo cultured and 
stimulated alveolar macrophages from patients with 
(COPD)20. Few weeks (1-8) therapy with 1,8-Cineole 
reduces exacerbations, dyspnea and specific airway 
resistance in patients with COPD and improves lung 
function parameters and health status by intervening in 
the mucus membrane pathophysiology of airway 
inflammation
14
. 
 
Antiviral activity of EEO: The antiviral activity of 
EEO was confirmed against an enveloped viruses 
(similar to COVID-19); mumps virus obtained from 
patients with respiratory tract infection21, herpes 
simplex virus before or during host cell adsorption22, 
H1N1 influenza virus
23and inhibits avian influenza virus 
H11N9 in aerosol, vapor and if being captured on a fiber 
coating materials9. The inhibitory mechanism of EEO 
is based on the inactivation of hemagglutinin protein of 
the virus in its vapor phase9. As well, two preprint 
articles by (Sharma et al.) demonstrated that eucalyptol 
(1,8 cineole) and Jensenone from EEO represent 
potential COVID-19 main viral proteinase (M-
pro/3CLpro) inhibitory effect by molecular docking 
studies. Inhaling concentrated EEO vapors for 30 
minutes followed by periodical inhaling vapor mixture 
of EEO and tea tree oil (TTO) (50:50) with 30-120 
minutes intervals; reduces the risk of infection with 
SARS-CoV which is a highly pathogenic 
coronavirus23,24.  
Co-infection control activity of EEO: The 
antibacterial potentials of EEO was confirmed by 
activity against respiratory infecting bacteria; 
Haemophilus influenzae, H. parainfluenzae, 
Stenotrophomonas maltophilia and Streptococcus 
pneumoniae21 and by inhalation prophylactic use 
against colds, tuberculosis, flus and opportunistic 
infections of the human respiratory system24. In 
hospitals EEO used for controlling multidrug-resistant 
bacteria25, reduce endotracheal tube biofilm microbial 
contamination during ventilation process26 and showed 
antifungal potential against intensive care units (ICU) 
isolated yeast24,27. EEO fumes inhalation affords 
bactericidal components killing infections in the nasal 
passages, sinuses, bronchial tubes and lungs24.  
Anti-inflammatory and Immune modulation 
potentials of EEO: Dexamethasone today is the first 
and only drug that has made a significant difference to 
patient mortality for COVID-19 due to its anti-
inflammatory and immune modulation effects. 
Surprisingly EEO can implement the innate cell-
mediated immune response and anti-inflammatory 
properties28,29. COVID-19 hospitalized patients 
developed at latter phase a syndrome known as 
cytokine storm or hyperinflammatory syndrome due to 
immune overactivation that increases the acute 
respiratory distress and can lead to death30. 
Pretreatment with EEO markedly reduced the 
production of proinflammatory cytokines which 
indicates that EEO might have its potential to stop 
cytokine storm19. As well suppression of human lung 
macrophages inflammatory responses by EEO and its 
constituent 1,8-cineole was reported31.  
Other activities of EEO: EEO decreasing patient’s 
pain32, cough treatment33, aid in the recovery from 
certain respiratory diseases24, air freshener, fumigating 
agent34 and effective in cleaning mixtures for 
degreasing, deodorizing and disinfection33,35.  
Dose and safety of EEO: The WHO monograph EEO 
reported doses were 12drops /150mL or 1.5% v/v 
solution boiling water for inhalation three times 
daily36,37. The oral LD50 in rats (2.5g/kg)
38. A 
toxicological study influenced the use of EEO with 
certain concentration less than (233.44 mg/kg) to avoid 
serious metabolic and cellular damage39. As well, EEO 
also may cause irritation to the skin, toxic effects 
especially in children and adverse effects as slurred 
speech, ataxia, muscle weakness progressing to 
unconsciousness and seizures if used in high 
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concentration40-42. Because of EEO strong odor, an 
accidental poisoning is not common, as intoxication 
occurs only via oral consumption of 4-5ml EEO5. 
There is no danger of accumulating inhaled essential 
oils in the body even with repeated inhalation as the 
concentration of inhaled EOs decreases to half its 
original value within 30-40 minutes24. However the oils 
liquid phase are generally irritant and possibly toxic for 
nasopharyngeal and lung epithelial cells, the vapor 
phase of the same oils might be useful as inhalers for 
respiratory infections in low concentrations15. Studies 
on 1,8-cineole confirmed that it is well absorbed from 
breathing air. Upon inhalation of 2 ml 1,8-cineole 99% 
for 20 min. the blood serum concentration was 
increasing in a linear way with distribution half-life 2-
13 min. and elimination half-life 31-281 min. 
Clinical trials of EEO on human volunteers: The 
effect of 0.25ml EEO inhalation for 10 minutes on 
cardiovascular responses using a disposable face mask 
was reported in (ClinicalTrials.gov Identifier: 
NCT02656004) and smelling of pure EEO in vial for 
training of the olfactory nerve for improving smell 
sense after radiation therapy also reported in 
(ClinicalTrials.gov Identifier: NCT03049358).  EEO 
100% concentration was confirmed as a safe method of 
protection from mosquito bites on human volunteers 
skin in indoor conditions34. Inhalation of EEO was 
effective in reducing blood pressure and pain after total 
knee replacement32. Another clinical study had 
concluded that the treatment with 1,8-cineole of 
patients with acute non-purulent rhinosinusitis was 
effective and safe with only mild side effects and can 
avoid antibiotic treatment43. Another study had 
concluded that acute rhinosinusitis can be managed 
by treatment with 1,8-cineole and confirmed its safety 
and significant benefit for bronchitis44.  
Precautions for using EEO: EEO should not be used 
during pregnancy or lactation as there is no information 
available on inhalation of EEO or its main constituent 
1,8-cineole for pregnant women and 1,8-cineole has 
been reported to penetrate the rodents placenta. EEO 
should not be used for babies and very young children 
less than 12 years as the risk of reflex spasm is 
expected. 
 
CONCLUSION 
Off-label use of EEO as an inhaler via inhalation 
vaporizers, diffusers or as a fragrance in cleaning 
mixtures should be announced as a concomitant safe 
hygienic lifestyle to hand washing, face mask wearing 
and social distancing. The use of EEO for COVID-19 
patients will reduce muscle and stomach pain, cough 
and dyspnea which are the common symptoms, and 
protect patients from co-infection susceptibility and 
decrease chance of hyper inflammatory syndrome and 
COPD associated risk morbidity. Researchers should 
start the clinical trials and in vivo studies on EEO 
safety and efficacy as soon as possible to confirm or 
reject its antiviral potentials against COVID-19 to 
evaluate the possibility of its use for treatment and/or 
prevention. Community pharmacies and essential oil 
manufactories should sell EEO just as an off-label drug 
not as treatment or preventative protocol for COVID-
19 pandemic. 
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